Gliadel + Avastin + Temodar
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme, Gliosarcoma
Trial Timeline
Apr 1, 2011 → Jun 16, 2014
NCT ID
NCT01186406About Gliadel + Avastin + Temodar
Gliadel + Avastin + Temodar is a phase 2 stage product being developed by Eisai for Glioblastoma Multiforme. The current trial status is terminated. This product is registered under clinical trial identifier NCT01186406. Target conditions include Glioblastoma Multiforme, Gliosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01186406 | Phase 2 | Terminated |
Competing Products
20 competing products in Glioblastoma Multiforme